Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUID
7 hours ago
- #survival benefits
- #hepatocellular carcinoma
- #neoadjuvant therapy
- Neoadjuvant triple therapy (transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors) improves survival in resectable hepatocellular carcinoma (HCC).
- The study involved 583 patients across 20 Chinese medical centers (2019-2023), comparing neoadjuvant triple therapy (n=205) vs. direct hepatectomy (n=378).
- Patients receiving neoadjuvant therapy showed significantly higher overall survival (OS) and longer median event-free survival (EFS) (19.7 vs. 10.9 months).
- Subgroup analysis confirmed better OS and EFS for those who underwent hepatectomy after neoadjuvant therapy compared to direct surgery.
- Complete pathologic response rate was 34.0% with neoadjuvant triple therapy.
- The treatment was associated with higher rates of serious adverse events and postoperative complications (e.g., hepatic insufficiency, bile leakage, ascites).
- Neoadjuvant triple therapy offers survival benefits but requires careful risk-benefit assessment due to complications.